Close Menu
October 22, 2020
Sponsored by
Sophia Genetics

Adoption of Broad NGS Profiling for HRR Deficiency: Looking Beyond BRCA, SNPs, and Indels

GenomeWebinar

Assistant Professor, University of Lorraine,
Tumor Molecular Biology Unit, Institut de Cancérologie de Lorraine

This webinar will share the Lorraine Cancer Institute's experience in implementing a novel targeted solution to accurately assess homologous recombination repair (HRR) deficiency by analyzing a series of genes, beyond BRCA, and calling multiple types of variants, including copy number variants (CNVs). In the past, HRR deficiency has been commonly associated with BRCA mutations, but recent evidence shows that HRR deficiency detection should not exclusively focus on BRCA, single nucleotide variants (SNPs), and insertions/deletions (indels).

The Lorraine Cancer Center is currently participating in a guideline-defining multicenter study on ovarian cancer, investigating the correlations between a larger range of genomic alterations linked to HRR, clinical evolution, and therapeutic impact.

Dr. Alexandre Harlé, from the institute's Tumor Biology Unit, will describe the adoption of a next-generation sequencing (NGS) solution for broad HRR-deficiency-analysis, additionally enabling CNV detection. He will discuss:

• Why the institute chose a broad and future-proof HRR-deficiency-analysis approach

• How a single NGS workflow can assess a large range of HRR-related variants

• The methods used to confirm the analytical performance of the solution

• The challenges lying ahead and how can they be solved

Sponsored by

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
24
Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.